Shots:
- Argo has entered into an additional strategic collaboration with Novartis for multiple CV assets
- Novartis has obtained an option to license ex-China rights to two discovery-stage molecules for sHTG & mixed dyslipidemia, plus first negotiation rights to BW-00112 (ANGPTL3), a P-II asset. Deal also incl. a reciprocal P&L-sharing license for a hepatic siRNA asset expected to start P-I in 2026, with Novartis receiving ex-China rights & a China P&L option & while Argo retains the US P&L option
- As per the deal, Argo will receive $160M upfront, ~$5.2B in milestones & option payments, with tiered royalties, plus Novartis has also indicated a non-binding intention to join Argo’s next equity financing round
Ref: Argo| Image: Argo & Novartis | Press Release
Related News:- Arrowhead Enters a ~$2.2B Deal with Novartis for ARO-SNCA and TRiM-Based Therapies to Treat Neurodegenerative Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
